Log in

CVE:MPHMedicure Stock Price, Forecast & News

Today's Range N/A
50-Day Range
MA: C$1.05
52-Week Range N/A
Volume100 shs
Average Volume11,903 shs
Market CapitalizationC$10.80 million
P/E RatioN/A
Dividend YieldN/A
Medicure Inc., a cardiovascular pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, and Barbados. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non ST elevated acute coronary syndrome. The company's products also comprise PREXXARTAN, an oral solution used for the treatment of hypertension. In addition, it is developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications; and products for the treatment of acute cardiology. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesC$18.30 million
Book ValueC$2.50 per share



Market CapC$10.80 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive MPH News and Ratings via Email

Sign-up to receive the latest news and ratings for MPH and its competitors with MarketBeat's FREE daily newsletter.

Medicure (CVE:MPH) Frequently Asked Questions

When is Medicure's next earnings date?

Medicure is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Medicure.

How were Medicure's earnings last quarter?

Medicure Inc. (CVE:MPH) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter. The firm earned $3.01 million during the quarter. View Medicure's earnings history.

Has Medicure been receiving favorable news coverage?

News stories about MPH stock have been trending very negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medicure earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Medicure.

Who are some of Medicure's key competitors?

What other stocks do shareholders of Medicure own?

Who are Medicure's key executives?

Medicure's management team includes the following people:
  • Dr. Albert David Friesen, Founder, Chairman, CEO & Pres (Age 72)
  • Mr. James F. Kinley, CFO & Sec. (Age 41)

What is Medicure's stock symbol?

Medicure trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MPH."

How do I buy shares of Medicure?

Shares of MPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is Medicure?

Medicure has a market capitalization of C$0.00 and generates C$18.30 million in revenue each year.

What is Medicure's official website?

The official website for Medicure is www.medicure.com.

How can I contact Medicure?

Medicure's mailing address is 1250 Waverley St Suite 2, WINNIPEG, MB R3T 6C6, Canada. The company can be reached via phone at +1-204-4877412.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.